NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CNB Financial Corporation (NASDAQ:CCNE), Akebia Therapeutics, Inc. (NASDAQ:AKBA), Mesoblast Limited (NASDAQ:MESO), 21Vianet Group, Inc. (NASDAQ:VNET), Old Line Bancshares, Inc. (NASDAQ:OLBK), and BioSpecifics Technologies Corp (NASDAQ:BSTC), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

CCNE DOWNLOAD: http://Fundamental-Markets.com/register/?so=CCNE
AKBA DOWNLOAD: http://Fundamental-Markets.com/register/?so=AKBA
MESO DOWNLOAD: http://Fundamental-Markets.com/register/?so=MESO
VNET DOWNLOAD: http://Fundamental-Markets.com/register/?so=VNET
OLBK DOWNLOAD: http://Fundamental-Markets.com/register/?so=OLBK
BSTC DOWNLOAD: http://Fundamental-Markets.com/register/?so=BSTC

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine CNB Financial Corporation (NASDAQ:CCNE), Akebia Therapeutics, Inc. (NASDAQ:AKBA), Mesoblast Limited (NASDAQ:MESO), 21Vianet Group, Inc. (NASDAQ:VNET), Old Line Bancshares, Inc. (NASDAQ:OLBK), and BioSpecifics Technologies Corp (NASDAQ:BSTC) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 14th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

CNB FINANCIAL CORPORATION (CCNE) REPORT OVERVIEW

CNB Financial's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, CNB Financial reported interest income of $28.70MM vs $24.82MM (up 15.63%) and basic earnings per share $0.23 vs $0.35 (down 34.29%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, CNB Financial reported interest income of $108.87MM vs $94.32MM (up 15.44%) and basic earnings per share $1.57 vs $1.42 (up 10.56%). CNB Financial is expected to report earnings on April 16th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.43. The estimated EPS forecast for the next fiscal year is $2.56 and is expected to report on February 1st, 2019.

To read the full CNB Financial Corporation (CCNE) report, download it here: http://Fundamental-Markets.com/register/?so=CCNE

-----------------------------------------

AKEBIA THERAPEUTICS, INC. (AKBA) REPORT OVERVIEW

Akebia Therapeutics' Recent Financial Performance

For the twelve months ended December 31st, 2017 vs December 31st, 2016, Akebia Therapeutics reported revenue of $177.98MM vs $1.54MM (up 11,495.05%) and basic earnings per share -$1.77 vs -$3.60. Akebia Therapeutics is expected to report earnings on May 8th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$1.15. The estimated EPS forecast for the next fiscal year is -$1.33 and is expected to report on March 11th, 2019.

To read the full Akebia Therapeutics, Inc. (AKBA) report, download it here: http://Fundamental-Markets.com/register/?so=AKBA

-----------------------------------------

MESOBLAST LIMITED (MESO) REPORT OVERVIEW

Mesoblast's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Mesoblast reported revenue of $13.40MM vs $0.55MM (up 2,335.82%) and basic earnings per share $0.15 vs -$0.25. For the twelve months ended June 30th, 2017 vs June 30th, 2016, Mesoblast reported revenue of $2.41MM vs $42.55MM (down 94.33%) and basic earnings per share -$0.97 vs -$0.06. Mesoblast is expected to report earnings on May 23rd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.12. The estimated EPS forecast for the next fiscal year is -$0.42 and is expected to report on September 4th, 2018.

To read the full Mesoblast Limited (MESO) report, download it here: http://Fundamental-Markets.com/register/?so=MESO

-----------------------------------------

21VIANET GROUP, INC. (VNET) REPORT OVERVIEW

21Vianet Group's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, 21Vianet Group reported revenue of $133.17MM vs $145.16MM (down 8.26%) and basic earnings per share -$1.98 vs -$0.13. For the twelve months ended December 31st, 2016 vs December 31st, 2015, 21Vianet Group reported revenue of $524.53MM vs $561.05MM (down 6.51%) and basic earnings per share -$0.90 vs -$0.78. 21Vianet Group is expected to report earnings on May 24th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.11. The estimated EPS forecast for the next fiscal year is -$0.04 and is expected to report on March 11th, 2019.

To read the full 21Vianet Group, Inc. (VNET) report, download it here: http://Fundamental-Markets.com/register/?so=VNET

-----------------------------------------

OLD LINE BANCSHARES, INC. (OLBK) REPORT OVERVIEW

Old Line Bancshares' Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Old Line Bancshares reported interest income of $20.43MM vs $16.35MM (up 24.94%) and basic earnings per share $0.48 vs $0.39 (up 23.08%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Old Line Bancshares reported interest income of $73.61MM vs $60.46MM (up 21.75%) and basic earnings per share $1.38 vs $1.21 (up 14.05%). Old Line Bancshares is expected to report earnings on May 4th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.36. The estimated EPS forecast for the next fiscal year is $2.55 and is expected to report on January 22nd, 2019.

To read the full Old Line Bancshares, Inc. (OLBK) report, download it here: http://Fundamental-Markets.com/register/?so=OLBK

-----------------------------------------

BIOSPECIFICS TECHNOLOGIES CORP (BSTC) REPORT OVERVIEW

BioSpecifics Technologies' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, BioSpecifics Technologies reported revenue of $6.52MM vs $6.88MM (down 5.32%) and basic earnings per share $0.38 vs $0.43 (down 11.63%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, BioSpecifics Technologies reported revenue of $26.25MM vs $22.75MM (up 15.39%) and basic earnings per share $1.61 vs $1.41 (up 14.18%). BioSpecifics Technologies is expected to report earnings on May 9th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.46.

To read the full BioSpecifics Technologies Corp (BSTC) report, download it here: http://Fundamental-Markets.com/register/?so=BSTC

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: [email protected]

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.